Pharmacotherapy of dilated cardiomyopathy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F15%3A00061406" target="_blank" >RIV/00159816:_____/15:00061406 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/15:00082269 RIV/65269705:_____/15:00061406
Result on the web
<a href="http://dx.doi.org/10.2174/138161282104141204141851" target="_blank" >http://dx.doi.org/10.2174/138161282104141204141851</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/138161282104141204141851" target="_blank" >10.2174/138161282104141204141851</a>
Alternative languages
Result language
angličtina
Original language name
Pharmacotherapy of dilated cardiomyopathy
Original language description
The pharmacological treatment of dilated cardiomyopathy overlaps with the treatment of heart failure. The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All patients, including those withasymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic heart failure NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. Digoxin is recommended in the event of atrial fibrillation, and otherwise only in the event of NYHA III and IV. Ivabradine is recommended for patients with sinus rhythm and pulse rate of > 70/min. In decompensation of heart failure, dobutamine, phosphodiesterase inhibitors or levosimendan are administered over the short-term. Of the recent treatment options
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: St. Anne´s University Hospital Brno - International Clinical Research Center (FNUSA-ICRC)</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Pharmaceutical Design
ISSN
1381-6128
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
4
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
10
Pages from-to
449-458
UT code for WoS article
000349458700003
EID of the result in the Scopus database
—